Regeneron v Kymab – Principles capable of general application
Read more >
Featured Insights: Biotechnology & Pharmaceuticals
Seeing Article 3(d) with 2020 vision – revisited
Read more >
Regeneron v Kymab – Sufficiency explained through transgenic mice and teleporters
Read more >
The End of (Interrupted) Days is Nigh
Read more >
The slow death of Neurim – will SPCs for new indications soon be a thing of the past...
Read more >
Interpreting Article 3(a) of supplementary protection certificates (SPCs) regulation with ...
Read more >
A fight against time: Coronavirus vs Biotechnology
Read more >
Artificial intelligence and antibiotics: overcoming excluded subject-matter hurdles
Read more >
A Whistlestop Guide to SPCs
Read more >
Seeing Article 3(d) with 2020 vision
Read more >
Option is a failure with combination SPCs
Read more >
What does the US-China trade deal mean for pharmaceutical patent holders?
Read more >
Patents are only part of the pharma picture
Read more >
Antibodies at the European Patent Office
Read more >
Supplementary Protection Certificate (SPC) Manufacturing Waiver – Article 5 goes epic
Read more >
Third time lucky? EPO Enlarged Board of Appeal referred issue of plant patentability again
Read more >
Lost in translation: Are animal models predictive of a treatment effect?
Read more >
Substance or device – a distinction without a difference?
Read more >
Plausibility and non-working embodiments
Read more >
US claim construction at the English High Court – Chugai Pharmaceuticals Co. Ltd v U...
Read more >